Intech Investment Management LLC decreased its position in Cencora, Inc. (NYSE:COR – Free Report) by 26.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 22,120 shares of the company’s stock after selling 8,116 shares during the period. Intech Investment Management LLC’s holdings in Cencora were worth $6,642,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cardiff Park Advisors LLC purchased a new stake in shares of Cencora in the 3rd quarter worth $734,000. Hantz Financial Services Inc. grew its position in shares of Cencora by 13.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,592 shares of the company’s stock worth $480,000 after buying an additional 191 shares in the last quarter. Pensioenfonds Rail & OV bought a new position in shares of Cencora during the 3rd quarter worth $9,797,000. IFG Advisory LLC increased its stake in shares of Cencora by 10.0% during the third quarter. IFG Advisory LLC now owns 850 shares of the company’s stock valued at $255,000 after buying an additional 77 shares during the period. Finally, Phoenix Financial Ltd. increased its stake in shares of Cencora by 14.6% during the third quarter. Phoenix Financial Ltd. now owns 2,445 shares of the company’s stock valued at $734,000 after buying an additional 312 shares during the period. Institutional investors own 97.52% of the company’s stock.
Insider Buying and Selling at Cencora
In related news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares in the company, valued at $6,305,754.60. This represents a 36.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.38% of the stock is owned by company insiders.
Cencora Stock Performance
Shares of NYSE:COR opened at $350.14 on Wednesday. The firm has a 50 day moving average of $328.17 and a 200 day moving average of $317.23. The company has a quick ratio of 0.59, a current ratio of 0.94 and a debt-to-equity ratio of 3.01. The company has a market capitalization of $66.82 billion, a price-to-earnings ratio of 19.54, a price-to-earnings-growth ratio of 1.85 and a beta of 0.58. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54.
Cencora (NYSE:COR – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.08. Cencora had a return on equity of 110.72% and a net margin of 1.03%. The business had revenue of $88.35 billion for the quarter, compared to analysts’ expectations of $87.95 billion. During the same quarter last year, the firm earned $3.84 EPS. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, sell-side analysts predict that Cencora, Inc. will post 19.58 earnings per share for the current fiscal year.
Cencora Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be paid a dividend of $0.66 per share. This is an increase from Cencora’s previous quarterly dividend of $0.60. The ex-dividend date is Friday, November 13th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is currently 14.73%.
Analyst Ratings Changes
COR has been the subject of several recent research reports. UBS Group decreased their price objective on Cencora from $430.00 to $400.00 and set a “buy” rating for the company in a report on Friday, October 16th. Robert W. Baird upped their price objective on shares of Cencora from $373.00 to $375.00 and gave the stock an “outperform” rating in a research note on Thursday, October 22nd. Wells Fargo & Company increased their target price on shares of Cencora from $395.00 to $400.00 and gave the stock an “overweight” rating in a report on Tuesday. Bank of America increased their target price on shares of Cencora from $285.00 to $310.00 in a report on Tuesday, July 21st. Finally, Argus raised their target price on shares of Cencora from $340.00 to $380.00 and gave the company a “buy” rating in a research report on Tuesday, October 20th. Thirteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $376.36.
Check Out Our Latest Analysis on Cencora
About Cencora
Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.
Featured Articles
- Five stocks we like better than Cencora
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
